DDInter1043 DDInter927
Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Levacetylmethadol {u} (Compound) resembles {v} (Compound) Disopyramide
Levacetylmethadol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Levacetylmethadol {u} (Compound) binds {v} (Gene) CYP19A1
Levacetylmethadol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Levacetylmethadol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Levacetylmethadol {u} may lead to a major life threatening interaction when taken with {v} Alvimopan
Levacetylmethadol {u} may lead to a major life threatening interaction when taken with {v} Naltrexone
Levacetylmethadol {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenoxylate
Levacetylmethadol {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Doxylamine
Levacetylmethadol (Compound) resembles Disopyramide (Compound)
Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Levacetylmethadol (Compound) binds CYP19A1 (Gene)
Levacetylmethadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Levacetylmethadol may lead to a major life threatening interaction when taken with Alvimopan
Levacetylmethadol may lead to a major life threatening interaction when taken with Naltrexone
Levacetylmethadol (Compound) resembles Diphenoxylate (Compound) and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Levacetylmethadol (Compound) resembles Doxylamine (Compound) and Levacetylmethadol may lead to a major life threatening interaction when taken with Doxylamine